Question explored with the scientific record
Are biologics good for Crohn's?
Biologics can improve symptoms and reduce surgery in Crohn’s disease, but the evidence is built on manufacturer-funded trials, surrogate endpoints, and comparisons that hide the full risk picture.
The evidence for anti-TNF drugs like infliximab and adalimumab comes mostly from industry-sponsored trials that measure remission by symptom scores (CDAI) or endoscopic appearance, not by hard outcomes like death or disability [4]. A meta-analysis of these trials found that about 44% of Crohn’s patients relapse within a year of stopping anti-TNF therapy, and the relapse rate climbs to 50-80% beyond five years [1][5]. That same meta-analysis noted that re-treatment works in about 80% of cases, but it also means the drug is a management tool, not a cure [5]. The CHARM trial for adalimumab showed 36-41% remission at one year, but the placebo group was not followed long-term for comparison [4]. The Accent I trial for infliximab found 39-45% remission with scheduled dosing versus 21% with episodic dosing, but again the comparison is between two treated groups, not against untreated natural history [4].
Newer biologics like ustekinumab and vedolizumab show similar patterns. A real-world Australian registry found that 80% of Crohn’s patients stayed on ustekinumab at 12 months, compared to 64% on adalimumab [13]. But persistence is not the same as cure; it means the drug was tolerated, not that it eliminated the disease. Ustekinumab’s UNITI trials showed clinical response in about 34% of anti-TNF-experienced patients at week 6, versus 22% on placebo [10]. That is a real but modest benefit. Vedolizumab in Crohn’s disease showed clinical remission rates of only 20-22% at 12 months in real-world cohorts, and endoscopic remission was even lower at 19-26% [14][9]. For perianal fistulizing disease, anti-TNF therapy combined with seton drainage achieved about 53% complete remission over a median 4-year follow-up, but recurrence was 10% [2]. Ustekinumab for fistulas showed a 64% response rate at 52 weeks in a small study of 18 patients, but no complete fistula closure was observed [11].
The safety data is thin. The TREAT registry found that infection risk was not significantly increased with infliximab alone, but corticosteroids were a major confounder [4]. Serious adverse events in the certolizumab trial were 5.4% versus 3.7% on placebo, and one malignancy occurred in the treatment arm [6]. The GEMINI trials for vedolizumab reported no cases of PML in controlled studies, but a single case occurred in an HIV-positive patient on prolonged immunosuppression [12]. Peripheral neuropathy occurred in 50% of pediatric patients on thalidomide, a drug sometimes used as rescue therapy [3]. The long-term safety data for these biologics beyond 5 years is largely absent from the published record.
| Drug | 12-month remission (Crohn’s) | Relapse after stopping | Serious adverse events |
|---|---|---|---|
| Infliximab | 39-45% (scheduled) [4] | 44% at 1 year [5] | Not significantly elevated vs placebo in TREAT [4] |
| Adalimumab | 36-41% [4] | Similar to infliximab [5] | Comparable to placebo in trials [4] |
| Ustekinumab | 28% clinical remission at 12 months [7] | Not well studied | Low immunogenicity, but dose escalation common [8] |
| Vedolizumab | 20-22% clinical remission [14] | 33% loss of response over time [9] | No PML in controlled trials, but one case in HIV patient [12] |
My call: biologics offer real but modest benefits for Crohn’s disease, mainly in symptom reduction and reduced surgery rates, but the evidence is dominated by manufacturer-funded trials, uses surrogate endpoints, and lacks long-term safety data. The risk of relapse after stopping is high, and the drugs do not cure the disease. For a patient with moderate-to-severe Crohn’s who has failed other therapies, the benefit may outweigh the risk, but the decision should be made with full awareness that the evidence base is thinner and more conflicted than the promotional literature suggests. Confidence: moderate.
Sources used 14
-
Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros
A narrative review weighing the pros and cons of stopping anti-TNF therapy in Crohn's disease patients in sustained remission, highlighting potential benefits (reduced toxicity, patient empowerment, cost savings) alongside substantial relapse risk, and noting that a subset achie…
DOI: 10.1159/000520942 -
PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
A multicenter Brazilian retrospective study evaluating complete perianal remission after combined therapy (seton placement during EUA followed by anti-TNF therapy) for perianal fistulizing Crohn's disease, reporting about half achieved remission with low recurrence over a median…
DOI: 10.1590/S0004-28032014000400004 -
Thalidomide Use and Outcomes in Pediatric Patients With Crohn Disease Refractory to Infliximab and Adalimumab
Thalidomide rescue therapy in pediatric Crohn disease refractory to anti-TNF treatment induces clinical remission and fistula closure with steroid-sparing effects and reduced surgeries, but peripheral neuropathy is a notable adverse event.
DOI: 10.1097/mpg.0b013e318228349e -
Anti-TNF-alpha treatment strategies: results and clinical perspectives
Anti-TNF therapies significantly improve induction and maintenance of remission in Crohn's disease and ulcerative colitis, with evidence that early treatment and optimized regimens enhance outcomes but safety concerns and immunogenicity require careful management.
DOI: 10.1016/S0399-8320(09)73156-2 -
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐ TNF therapy
A comprehensive systematic review and meta-analysis assessing factors associated with relapse after discontinuation of anti-TNF therapy in inflammatory bowel disease, finding about 44% relapse in Crohn's disease and 38% in ulcerative colitis, with endoscopic and biomarker-inform…
DOI: 10.1111/apt.13276 -
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
A multicenter, randomized, double-blind, placebo-controlled trial evaluating certolizumab pegol for induction therapy in adults with active Crohn's disease naive to anti-TNF, which showed no statistically significant week-6 remission overall but suggested benefit in subgroups wi…
DOI: 10.1016/j.cgh.2011.04.031 -
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort
This study evaluates the real-world effectiveness of ustekinumab in achieving clinical, endoscopic, and radiographic responses in Crohn's disease patients who are refractory to anti-TNF therapy, demonstrating significant response rates over time.
DOI: 10.1111/apt.14016 -
Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
Exposure–response relationships exist for ustekinumab, vedolizumab, and tofacitinib in inflammatory bowel disease, but the clinical utility of therapeutic drug monitoring to optimize treatment with these agents remains uncertain.
DOI: 10.3390/jcm10061242 -
P704 Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s disease
This study evaluates the efficacy of vedolizumab in inducing and maintaining clinical and objective remission in a large cohort of patients with moderate-to-severe Crohn's disease, revealing that while vedolizumab is effective for many, a significant portion of patients experien…
DOI: 10.1093/ecco-jcc/jjx180.831 -
Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease
A comprehensive review of the IL-23/IL-17 axis in inflammatory bowel disease (IBD), evaluating the efficacy and safety of IL-12/23p40 and IL-23p19–targeting therapies (e.g., ustekinumab, briakinumab, risankizumab, MEDI2070) and anti-IL-17 agents, and highlighting that IL-23 bloc…
DOI: 10.1080/14712598.2017.1258399 -
Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study
Ustekinumab produced a meaningful fistula response in a majority of 18 adults with active perianal fistulizing Crohn disease over 52 weeks, with good tolerability but no observed fistula remission, suggesting potential benefit and the need for randomized trials.
DOI: 10.1093/ibd/izaa297 -
A product review of vedolizumab in inflammatory bowel disease
This article provides a comprehensive review of vedolizumab for inflammatory bowel disease, detailing its mechanism of action, preclinical and clinical development, pharmacokinetics/pharmacodynamics, immunogenicity, real-world use, safety, biomarkers, and prospects for personali…
DOI: 10.1080/21645515.2019.1591139 -
Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study
PANIC real-world data show ustekinumab persistence in Crohn's disease and vedolizumab persistence in ulcerative colitis are higher than anti-TNF agents, with adjusted hazards for persistence 0.56 (CD) and 0.61 (UC) and 12-month persistence rates of 80.0% vs 64.2% for ustekinumab…
DOI: 10.1111/apt.16436 -
Real‐world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease
Vedolizumab shows real-world efficacy in inducing and maintaining clinical and objective remission for Crohn's disease and ulcerative colitis in a large, single-centre Calgary cohort, with higher remission and mucosal healing observed in ulcerative colitis and a favorable safety…
DOI: 10.1111/apt.14919